Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In the latest session, Biogen Inc (NASDAQ: BIIB) closed at $113.38 down -5.90% from its previous closing price of $120.49. In other words, the price has decreased by -$5.90 from its previous closing price. On the day, 2.19 million shares were traded. BIIB stock price reached its highest trading level at $118.36 during the session, while it also had its lowest trading level at $110.24.
Ratios:
For a deeper understanding of Biogen Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.99 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.10. For the most recent quarter (mrq), Quick Ratio is recorded 0.90 and its Current Ratio is at 1.35. In the meantime, Its Debt-to-Equity ratio is 0.40 whereas as Long-Term Debt/Eq ratio is at 0.29.
On February 11, 2025, Bernstein started tracking the stock assigning a Mkt Perform rating and target price of $160.
Piper Sandler Downgraded its Overweight to Neutral on January 02, 2025, whereas the target price for the stock was revised from $315 to $138.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 07 ’25 when SHERWIN STEPHEN A sold 8,760 shares for $150.02 per share. The transaction valued at 1,314,142 led to the insider holds 11,318 shares of the business.
STEPHEN A SHERWIN bought 8,760 shares of BIIB for $1,290,961 on Mar 07 ’25. On Dec 09 ’24, another insider, Singhal Priya, who serves as the Head of Development of the company, sold 110 shares for $157.21 each. As a result, the insider received 17,293 and left with 5,426 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BIIB now has a Market Capitalization of 16595997696 and an Enterprise Value of 22342889472. As of this moment, Biogen’s Price-to-Earnings (P/E) ratio for their current fiscal year is 10.14, and their Forward P/E ratio for the next fiscal year is 7.20. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1013.98. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.79 while its Price-to-Book (P/B) ratio in mrq is 0.99. Its current Enterprise Value per Revenue stands at 2.309 whereas that against EBITDA is 7.458.
Stock Price History:
The Beta on a monthly basis for BIIB is 0.14, which has changed by -0.42789382 over the last 52 weeks, in comparison to a change of 0.028231144 over the same period for the S&P500. Over the past 52 weeks, BIIB has reached a high of $238.00, while it has fallen to a 52-week low of $110.04. The 50-Day Moving Average of the stock is -18.14%, while the 200-Day Moving Average is calculated to be -34.56%.
Shares Statistics:
For the past three months, BIIB has traded an average of 1.69M shares per day and 2127280 over the past ten days. A total of 145.80M shares are outstanding, with a floating share count of 145.62M. Insiders hold about 0.51% of the company’s shares, while institutions hold 91.03% stake in the company. Shares short for BIIB as of 1741910400 were 3310573 with a Short Ratio of 1.98, compared to 1739491200 on 3883735. Therefore, it implies a Short% of Shares Outstanding of 3310573 and a Short% of Float of 2.55.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
